Beijing Beiliu Pharmaceutical Co., Ltd. purchased 60 mu of land in Miyun County Industrial Development Zone to build a production base. The first phase of the project has been completed, and there are four production lines for water injection, tablets, granules and capsules. All workshops have passed GMP certification in National Medical Products Administration and put into production smoothly.
Beiliu Pharmaceutical Co., Ltd. has its own pharmaceutical research institute and a group of high-quality R&D personnel. The company will also introduce three kinds of Chinese medicines for treating anxiety, which will be the first Chinese patent medicine for treating anxiety in China. In order to maintain the company's sustainable competitiveness and meet the challenges faced by China's entry into WTO, the company has formulated the research and development direction of attaching equal importance to the development of contrast agent series products and natural medicine products, and cooperated with universities and scientific research institutions to focus on the development of natural medicines for the treatment of senile diseases and neuropsychiatric diseases, so that the company has been launching new products. The company has 0/23 employees, including nearly 80 professional and technical personnel. Concentric destiny is the cultural concept of Hokuriku, and people-oriented is Hokuriku's way of employing people. Over the years, it has attracted a group of outstanding talents to join us, including scholars and national experts who have returned from studying abroad. More than 50% of the company's middle managers have master's degrees. At the same time, the company attaches great importance to personnel training and sends key personnel to universities at home and abroad for further study, which promotes the improvement of the overall quality of the company. Hokuriku is convinced that outstanding talents are the source of enterprises' ability to maintain sustainable innovation.